Surescripts Settlement Shores Up Competition in E-Prescription Market

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • The FTC settled with Surescripts, LLC to resolve allegations that the health information technology company violated the FTC Act by engaging in anticompetitive, monopolistic conduct.
  • The FTC’s complaint alleged that Surescripts utilized anticompetitive tactics to maintain monopolies in two markets related to electronic prescriptions: routing, or transmission between a provider and a pharmacy; and eligibility, or transmission of a patient’s prescription coverage information between a pharmacy benefit manager and a provider. The FTC also alleged that Surescripts executed or enforced non-compete agreements with current and former employees.
  • Under the terms of the proposed order, Surescripts would be prohibited from engaging in anticompetitive conduct in routing and eligibility markets and in its medication history services and on-demand formulary services, which uses data that identifies the patient’s group or plan level prescription benefit information for a specific or alternative drug.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide